BIOCON Stock Overview
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Biocon Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹267.20 |
| 52 Week High | ₹307.10 |
| 52 Week Low | ₹217.50 |
| Beta | 0.42 |
| 1 Month Change | 8.73% |
| 3 Month Change | -3.22% |
| 1 Year Change | 16.43% |
| 3 Year Change | -33.09% |
| 5 Year Change | -13.83% |
| Change since IPO | 562.41% |
Recent News & Updates
Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?
Mar 20
Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next
Feb 12Recent updates
Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?
Mar 20Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next
Feb 12Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price
Jan 23Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price
Jan 03These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Nov 13Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
Aug 03Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50
Jul 03Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 02Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50
May 26Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)
Mar 28Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly
Feb 26Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate
Dec 17Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?
Sep 05Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 13Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate
May 26Is Biocon (NSE:BIOCON) Using Too Much Debt?
Mar 28Biocon (NSE:BIOCON) Seems To Use Debt Quite Sensibly
Dec 27Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
Nov 25Shareholder Returns
| BIOCON | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -4.0% | -5.0% | -2.1% |
| 1Y | 16.4% | 14.1% | 45.3% |
Return vs Industry: BIOCON exceeded the Indian Biotechs industry which returned 14.1% over the past year.
Return vs Market: BIOCON underperformed the Indian Market which returned 45.3% over the past year.
Price Volatility
| BIOCON volatility | |
|---|---|
| BIOCON Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: BIOCON has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOCON's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 16,545 | Siddharth Mittal | www.biocon.com |
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases.
Biocon Limited Fundamentals Summary
| BIOCON fundamental statistics | |
|---|---|
| Market cap | ₹319.03b |
| Earnings (TTM) | ₹12.00b |
| Revenue (TTM) | ₹146.13b |
26.6x
P/E Ratio2.2x
P/S RatioIs BIOCON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOCON income statement (TTM) | |
|---|---|
| Revenue | ₹146.13b |
| Cost of Revenue | ₹53.47b |
| Gross Profit | ₹92.66b |
| Other Expenses | ₹80.66b |
| Earnings | ₹12.00b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | 10.05 |
| Gross Margin | 63.41% |
| Net Profit Margin | 8.21% |
| Debt/Equity Ratio | 75.2% |
How did BIOCON perform over the long term?
See historical performance and comparison